Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Ziyang Cao"'
Autor:
Senlin Li, Xianzhu Yang, Zhenghai Zhang, Ziyang Cao, Liang Zhao, Xiao-Ding Xu, Dongdong Li, Yuxi Zhang
Publikováno v:
ACS Nano. 15:16030-16042
Effectively activating macrophages that can engulf cancer cells is a promising immunotherapeutic strategy but remains a major challenge due to the expression of "self" signals (e.g., CD47 molecules) by tumor cells to prevent phagocytosis. Herein, we
Publikováno v:
International Journal of Infectious Diseases, Vol 99, Iss, Pp 77-83 (2020)
Background Droplet digital PCR (ddPCR) is a technology that has higher sensitivity than real-time PCR for the identification of trace DNA. However, the use of ddPCR for the detection of Mycobacterium tuberculosis DNA in pathological samples has not b
Publikováno v:
Cancer Cytopathology. 128:545-552
BACKGROUND Epidermal growth factor receptor (EGFR) is an important marker for targeted therapy in patients with advanced non-small cell lung cancer (NSCLC). The samples obtained with minimally invasive biopsy techniques are usually small, and this li
Publikováno v:
ACS applied materialsinterfaces. 13(29)
Immunotherapy has revolutionized the therapeutic modalities of cancer treatment but is severely limited by a low objective response rate and the risk of immune-related side effects. Herein, an injectable supramolecular hydrogel is developed for local
Autor:
Gang Wang, Zhenghai Zhang, Zhongming Zhu, Liangjie Jin, Gengyun Sun, Ziyang Cao, Na Zhang, Xianzhu Yang
Publikováno v:
Biomaterials science. 9(9)
Local administration of therapeutic agents with long-term retention capabilities efficiently avoids nonspecific distribution in normal organs with an increased drug concentration in pathological tissue. Herein, we developed an injectable and degradab
Publikováno v:
ACS nano. 15(3)
Simultaneously targeting tumor cells and nonmalignant cells represent a more efficient strategy for replacing the traditional method of targeting only tumor cells, and co-delivery nanocarriers have inherent advantages to achieve this goal. However, d
Publikováno v:
J Thorac Dis
BACKGROUND: Cytology samples are the main resources to detect driver oncogene alterations for advanced lung cancer patients. To explore the value of liquid-based cytology in the detection of epidermal growth factor receptor (EGFR) mutation in non-sma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::63ec1664eabfbf987318d18ba6f1dfb5
https://europepmc.org/articles/PMC7578468/
https://europepmc.org/articles/PMC7578468/
Publikováno v:
Diagnostic Pathology
Diagnostic Pathology, Vol 15, Iss 1, Pp 1-7 (2020)
Diagnostic Pathology, Vol 15, Iss 1, Pp 1-7 (2020)
Background Non-surgical cytological specimens are adequate not only for accurate histological subtyping but also for molecular profiling. A modified amplification refractory mutation system polymerase chain reaction (ARMS PCR), known as SuperARMS PCR
Publikováno v:
Oncology Letters
Histone-lysine N-methyltransferase EZH2 (EZH2) is the principle component of the polycomb repressive complex 2 (PRC2)/embryonic ectoderm development protein-EZH2 complex, which promotes tumorigenesis by repressing transcription of tumor suppressor ge
Enhancement of chemosensitivity by WEE1 inhibition in EGFR-TKIs resistant non-small cell lung cancer
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 117, Iss, Pp-(2019)
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) is the first-line treatment in non-resectable non-small lung cancer (NSCLC) with EGFR mutation. However, EGFR-TIKs resistance would inevitably develop within 9–14 months afte